These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29779413)

  • 1. Tailoring tacrolimus therapy in kidney transplantation.
    Jouve T; Noble J; Rostaing L; Malvezzi P
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):581-588. PubMed ID: 29779413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
    Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L; Noble J; Terrec F; Bennani HN; Chevallier E; Janbon B; Germi R; Bugnazet M; Imerzoukene F; Malvezzi P; Rostaing L; Jouve T
    Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
    Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
    Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
    Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis.
    Azarfar A; Ravanshad Y; Mehrad-Majd H; Esmaeeli M; Aval SB; Emadzadeh M; Salehi M; Moradi A; Golsorkhi M; Khazaei MR
    Saudi J Kidney Dis Transpl; 2018; 29(6):1376-1385. PubMed ID: 30588970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
    Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
    Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.